Israel’s Alcobra will be the first launch by an Israeli life sciences company on Nasdaq since 2010. Alcobra’s MG01CI ADHD medication is undergoing a Phase II clinical trial. It is a non-stimulant treatment, which makes it safer than Ritalin and has far fewer side effects than Strattera.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000814140&fid=1725